Compare
Cencora, Inc. vs McKesson Corp vs Cardinal Health Inc vs Nu Skin Enterprises, Inc.
| Latest fiscal year | Cencora, Inc. COR | McKesson Corp MCK | Cardinal Health Inc CAH | Nu Skin Enterprises, Inc. NUS |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2026-03-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $321.33B | $403.43B | $254.25B | $1.49B |
| Revenue growth (YoY) | +9.3% | +12.4% | +14.2% | -14.3% |
| Gross margin | 3.6% | 3.6% | 3.8% | 69.4% |
| Operating margin | 0.8% | 1.5% | 1.0% | 4.4% |
| Net margin | 0.5% | 1.2% | 0.7% | 10.8% |
| Net income | $1.55B | $4.76B | $1.71B | $160.20M |
| EPS (Diluted) | $7.96 | $38.38 | $7.23 | $3.18 |
| Operating cash flow | $3.88B | $6.16B | $5.17B | $80.29M |
| Free cash flow | $3.21B | $5.72B | $4.53B | $46.01M |
| Cash & equivalents | $4.36B | $3.98B | $4.86B | $238.63M |
| Total assets | $76.59B | $82.32B | $57.30B | $1.41B |
| Total liabilities | n/a | n/a | n/a | $600.07M |
| Shareholders' equity | $1.51B | -$1.78B | -$2.88B | $805.24M |
| Return on year-end equity | 103.1% | n/a | n/a | 19.9% |
| Shares outstanding | 193.94M | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Cencora, Inc. | McKesson Corp | Cardinal Health Inc | Nu Skin Enterprises, Inc. |
|---|---|---|---|---|
| Latest | $321.33B Ended 2025-09-30 | $403.43B Ended 2026-03-31 | $254.25B Ended 2026-06-30 | $1.49B Ended 2025-12-31 |
| 1 year earlier | $293.96B Ended 2024-09-30 | $359.05B Ended 2025-03-31 | $222.58B Ended 2025-06-30 | $1.73B Ended 2024-12-31 |
| 2 years earlier | $262.17B Ended 2023-09-30 | $308.95B Ended 2024-03-31 | $226.83B Ended 2024-06-30 | $1.97B Ended 2023-12-31 |
| 3 years earlier | $238.59B Ended 2022-09-30 | $276.71B Ended 2023-03-31 | $204.98B Ended 2023-06-30 | $2.23B Ended 2022-12-31 |
| 4 years earlier | $213.99B Ended 2021-09-30 | $263.97B Ended 2022-03-31 | $181.33B Ended 2022-06-30 | $2.70B Ended 2021-12-31 |